Dendreon (NASDAQ:DNDN) is posting another day of impressive gains, and with today's high-single-digit move, the stock has gained about 75% from its early November lows. That's not to say things are looking great for the company -- all it takes is a glance at the stock price from early 2011 to remember just how far the maker of prostate cancer treatment Provenge has fallen. But as Brenton Flynn outlines in the video below, there's likely one simple explanation for the outsized gains we've seen over the past 90 days.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Bank of America, Dendreon, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.